52.09
-0.92(-1.74%)
Currency In USD
| Previous Close | 53.01 |
| Open | 52.21 |
| Day High | 54.22 |
| Day Low | 51.66 |
| 52-Week High | 59.39 |
| 52-Week Low | 29.31 |
| Volume | 2.56M |
| Average Volume | 1.82M |
| Market Cap | 6.23B |
| PE | -10.17 |
| EPS | -5.12 |
| Moving Average 50 Days | 37.6 |
| Moving Average 200 Days | 41.15 |
| Change | -0.92 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $7,058.27 as of September 08, 2025 at a share price of $52.09. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $2,315.11 as of September 08, 2025 at a share price of $52.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
GlobeNewswire Inc.
Aug 31, 2025 4:10 PM GMT
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillati
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
GlobeNewswire Inc.
Aug 30, 2025 7:18 AM GMT
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Ea
Cytokinetics to Participate in September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 8:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi’s 2025 Bi